431 related articles for article (PubMed ID: 18752564)
1. Animal models of NASH: getting both pathology and metabolic context right.
Larter CZ; Yeh MM
J Gastroenterol Hepatol; 2008 Nov; 23(11):1635-48. PubMed ID: 18752564
[TBL] [Abstract][Full Text] [Related]
2. Animal models of non-alcoholic steatohepatitis: of mice and man.
Schattenberg JM; Galle PR
Dig Dis; 2010; 28(1):247-54. PubMed ID: 20460919
[TBL] [Abstract][Full Text] [Related]
3. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
4. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
Larter CZ; Chitturi S; Heydet D; Farrell GC
J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
[TBL] [Abstract][Full Text] [Related]
5. Commonly used animal models of non-alcoholic steatohepatitis.
Fan JG; Qiao L
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):233-40. PubMed ID: 19502161
[TBL] [Abstract][Full Text] [Related]
6. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet.
Baumgardner JN; Shankar K; Hennings L; Badger TM; Ronis MJ
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G27-38. PubMed ID: 17947452
[TBL] [Abstract][Full Text] [Related]
7. Metabolic disturbances in non-alcoholic fatty liver disease.
Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression.
Farrell GC; Larter CZ; Hou JY; Zhang RH; Yeh MM; Williams J; dela Pena A; Francisco R; Osvath SR; Brooling J; Teoh N; Sedger LM
J Gastroenterol Hepatol; 2009 Mar; 24(3):443-52. PubMed ID: 19226377
[TBL] [Abstract][Full Text] [Related]
9. Interstrain differences in susceptibility to non-alcoholic steatohepatitis.
Yamazaki Y; Kakizaki S; Takizawa D; Ichikawa T; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2008 Feb; 23(2):276-82. PubMed ID: 17868334
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease from pathogenesis to management: an update.
Musso G; Gambino R; Cassader M
Obes Rev; 2010 Jun; 11(6):430-45. PubMed ID: 19845871
[TBL] [Abstract][Full Text] [Related]
11. Pathology of nonalcoholic fatty liver disease.
Yeh MM; Brunt EM
Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
[TBL] [Abstract][Full Text] [Related]
12. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats.
Nakano T; Cheng YF; Lai CY; Hsu LW; Chang YC; Deng JY; Huang YZ; Honda H; Chen KD; Wang CC; Chiu KW; Jawan B; Eng HL; Goto S; Chen CL
J Hepatol; 2011 Aug; 55(2):415-25. PubMed ID: 21184788
[TBL] [Abstract][Full Text] [Related]
13. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
Tessari P; Coracina A; Cosma A; Tiengo A
Nutr Metab Cardiovasc Dis; 2009 May; 19(4):291-302. PubMed ID: 19359149
[TBL] [Abstract][Full Text] [Related]
14. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
15. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease.
Gaemers IC; Stallen JM; Kunne C; Wallner C; van Werven J; Nederveen A; Lamers WH
Biochim Biophys Acta; 2011 Apr; 1812(4):447-58. PubMed ID: 21216282
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of NASH: animal models.
London RM; George J
Clin Liver Dis; 2007 Feb; 11(1):55-74, viii. PubMed ID: 17544972
[TBL] [Abstract][Full Text] [Related]
17. The liver and the waistline: Fifty years of growth.
Farrell GC
J Gastroenterol Hepatol; 2009 Oct; 24 Suppl 3():S105-18. PubMed ID: 19799688
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease.
Leclercq I
Bull Mem Acad R Med Belg; 2010; 165(3-4):147-55; discussion 155-8. PubMed ID: 21166266
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?
Ariz U; Mato JM; Lu SC; Martínez Chantar ML
Methods Mol Biol; 2010; 593():109-36. PubMed ID: 19957147
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Miele L; Forgione A; Gasbarrini G; Grieco A
Transl Res; 2007 Mar; 149(3):114-25. PubMed ID: 17320797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
